» Articles » PMID: 24449664

Understanding the Burden of Illness Associated with Hypoparathyroidism Reported Among Patients in the PARADOX Study

Overview
Journal Endocr Pract
Specialty Endocrinology
Date 2014 Jan 23
PMID 24449664
Citations 63
Authors
Affiliations
Soon will be listed here.
Abstract

Objective: Hypoparathyroidism is a rare disease caused by lack of parathyroid hormone (PTH) leading to hypocalcemia, hyperphosphatemia, and a variety of symptoms. This study aimed to quantify the clinical and social burden of illness from the perspective of affected patients.

Methods: A web-based instrument was developed with input from patients, clinical experts, and the Hypoparathyroidism Association. Qualifying participants were ≥18 years old, diagnosed with hypoparathyroidism for ≥6 months, and U.S. residents. Questions focused on demographics, diagnosis perceptions, current attitudes, medical management, current symptoms, acute episodes, comorbidities, personal life, and employment.

Results: A total of 374 adults (mean age, 49 ± 12 years; female, 85%) with hypoparathyroidism (mean duration, 13 ± 12 years; severe condition, 30.5%) completed the survey. Patients reported visiting a mean of 6 ± 8 physicians before and after their diagnosis. The majority strongly agreed with feeling unprepared to manage the condition at diagnosis (56%), that controlling their hypoparathyroidism is harder than expected (60%), and that they were concerned about long-term complications of their current medications (75%). More than 10 symptoms were experienced by 72% of patients in the preceding 12 months, despite current management regimens. Symptoms were experienced for a mean of 13 ± 9 hours/day. Hospital stays or emergency department visits were required by 79% of patients. 45% reported significant interference with their lives, 85% reported an inability to perform household activities, and 20% experienced a disease-associated change in employment status.

Conclusion: Patients with hypoparathyroidism have a high burden of illness and experience a broad spectrum of symptoms, with a multidimensional impact on their lives.

Citing Articles

Adaptation and validation of the French version of the Hypoparathyroid Patient Questionnaire 28 (HPQ28) in the ComPaRe-Epi-Hypo e-cohort.

Bertocchio J, Soyer J, Grosset N, Bessonies D, Nidercorn C, Sido C JBMR Plus. 2025; 9(3):ziaf011.

PMID: 39990279 PMC: 11845852. DOI: 10.1093/jbmrpl/ziaf011.


NIFTy: near-infrared fluorescence (NIRF) imaging to prevent postsurgical hypoparathyroidism (PoSH) after thyroid surgery-a phase II/III pragmatic, multicentre randomised controlled trial protocol in patients undergoing a total or completion....

Croft J, Ainsworth G, Corrigan N, Gordon K, Perry A, Twiddy M BMJ Open. 2025; 15(1):e092422.

PMID: 39890139 PMC: 11784174. DOI: 10.1136/bmjopen-2024-092422.


Hypoparathyroidism: Similarities and differences between Western and Eastern countries.

Yang Y, Deng Y, Sun L, Rejnmark L, Wang L, Pietschmann P Osteoporos Int. 2025; 36(3):391-402.

PMID: 39777494 DOI: 10.1007/s00198-024-07352-6.


Hypoparathyroidism after thyroidectomy: a matter of definition, experience and new adjuncts.

Kuczma P, Triponez F Gland Surg. 2024; 13(10):1873-1877.

PMID: 39544970 PMC: 11558303. DOI: 10.21037/gs-24-256.


Parathyroid gland identification and angiography classification using simple machine learning methods.

McEntee P, Greevy J, Triponez F, Demarchi M, Cahill R BJS Open. 2024; 8(5).

PMID: 39468722 PMC: 11518927. DOI: 10.1093/bjsopen/zrae122.